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SObjectives: Patients achieving a mediastinal pathologic complete response with neoadjuvant chemotherapy
have improved outcomes compared with patients with persistent N2 disease. How to best manage this latter
group of patients is unknown, prompting a review of our institutional experience.
Methods:All patients who initiated neoadjuvant therapy for non–small-cell lung cancer from 1995 to 2008 were
evaluated. The patients were excluded if they had received preoperative radiotherapy, had had a mediastinal
pathologic complete response, or had evidence of disease progression after neoadjuvant chemotherapy. The clin-
ical endpoints were calculated using the Kaplan-Meier product-limit method and compared using a log-rank test.
Results: A total of 28 patients were identified. The median follow-up period was 24 months. Several neoadju-
vant chemotherapy regimens were used, most commonly carboplatin with vinorelbine (36%) or paclitaxel
(32%). A partial response to chemotherapy was noted in 23 (82%) and stable disease was noted in 5 (18%)
on postchemotherapy imaging. Resection was performed in 22 of 28 patients, consisting of lobectomy in 14,
pneumonectomy in 2, and wedge/segmentectomy in 6 (21/22 R0, 1/22 R1). There were no postoperative deaths.
Postoperative therapy (radiotherapy and/or additional chemotherapy) was administered to 12 patients (55%).
The remaining 6 patients generally received definitive radiotherapy with or without additional chemotherapy.
The overall and disease-free survival rate at 1, 3, and 5 years was 75%, 37%, and 37% and 50%, 23%, and
19%, respectively. The survival rate at 5 years was similar between patients undergoing resection (34%) and
those receiving definitive radiotherapy with or without chemotherapy (40%; P ¼ .73).
Conclusions: Disease-free and overall survival was sufficiently high to warrant aggressive local therapy
(surgery or radiotherapy) in patients with persistent N2 disease after neoadjuvant chemotherapy. (J Thorac
Cardiovasc Surg 2011;142:1175-9)The optimal treatment approach for patients with operable
stage III (N2) non–small-cell lung cancer (NSCLC) is
controversial. Upfront surgery for patients with clinically
apparent N2 disease is unsatisfactory, with long-term sur-
vival rates less than 10%.1 However, a surgical approach,
incorporating neoadjuvant chemotherapy, is often used for
healthy patients with a minimal N2 disease burden.
Approximately 17% to 53% of patients achieve amediasti-
nal pathologic complete responsewith chemotherapyalone.2-9
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The Journal of Thoracic and Carpersistent N2 disease.2,8-13 For example, in a prospective
Phase II study evaluating neoadjuvant cisplatin and
docetaxel, pathologically negative mediastinal lymph nodes
after chemotherapy were associated with a significantly
improved 3-year survival rate compared with that for patients
with persistent N2 disease (61% vs 11%).2
Although persistent N2 disease after neoadjuvant che-
motherapy can be associated with inferior outcomes, the
optimal approach for these patients remains unclear.
Specifically, whether surgery should proceed despite an
incomplete pathologic response or whether a definitive
course of radiotherapy, with or without additional che-
motherapy, should be pursued is not known. We ex-
plored this further by evaluating our own experience at
the Duke University Medical Center.METHODS
This retrospective analysis was approved by the Duke University Med-
ical Center institutional review board. All patients with NSCLC who were
treated with neoadjuvant chemotherapy before planned surgical resection
were identified from the Duke Comprehensive Cancer Center’s registry.
Those patients with pathologically confirmed persistent N2 disease after
chemotherapy alone but no evidence of local or distant disease progression
were identified. Patients who were pN0-N1 after chemotherapy or had
evidence of local or distant disease progression were therefore excluded.
Any patients who received preoperative radiotherapy, including thosediovascular Surgery c Volume 142, Number 5 1175




















Involved N2 lymph node stationsy
1 Station 17 (61)
2 Stations 6 (21)
No sampling 5 (18)
Neoadjuvant chemotherapy
Carboplatin/second agentz 19 (68)







Data in parentheses are percentages. *TNM 7. yPer preoperative mediastinoscopy.
zVinorelbine, paclitaxel, docetaxel, or pemetrexed.
Abbreviations and Acronyms
CT ¼ computed tomography
NSCLC ¼ non–small-cell lung cancer
PET ¼ positron emission tomography
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Swith superior sulcus tumors, were excluded. The medical records and
pertinent radiologic imaging studies were reviewed to obtain the clinical,
surgical, and pathologic characteristics of each patient.
All patients underwent comprehensive staging studies initially to estab-
lish the extent of disease, including history and physical examination, im-
aging, and routine blood work. Pulmonary function tests were routinely
obtained, either during the initial workup or immediately before surgery.
After evaluation by a multidisciplinary team, including a thoracic surgeon,
medical oncologist, and radiation oncologist, neoadjuvant chemotherapy
was initiated. Because this was not standardized, a variety of regimens
were used.
Computed tomography (CT) or positron emission tomography (PET)/
CT imaging was obtained in all patients after they completed neoadjuvant
chemotherapy. In the absence of progressive disease, the patients then un-
derwent additional workup, including mediastinoscopy, video-assisted
thoracoscopic surgery, and/or thoracotomy, to assess the response to ther-
apy and evaluate for possible disease progression before the planned lung
resection. Based on the intraoperative assessment, resection proceeded at
the discretion of the thoracic surgeon. Additional therapy after surgery, spe-
cifically radiotherapy and/or additional chemotherapy, was recommended
at the discretion of the multidisciplinary team.
Statistical Analysis
Overall survival, disease-free survival, and local control were estimated
using the Kaplan-Meier product-limit method.14 Overall survival was cal-
culated from the date of diagnosis to the date of death. Patients were cen-
sored at the time of last follow-up. Disease-free survival was determined
from the date of diagnosis to the date of the first failure or death. Local
failures were cumulatively scored (ie, patients were not censored for local
failure at the point of distant failure). Comparisons in clinical outcomes
between patient subgroups were made using the log-rank test.15
RESULTS
Between 1995 and 2008, 301 patients were identified
who received neoadjuvant chemotherapy for NSCLC at
the Duke University Medical Center. Among these were
227 patients who also received neoadjuvant radiotherapy,
including patients with superior sulcus tumors (n ¼ 30),
who were excluded. Of the remaining 74 patients, 35
were pathologically N0-N1 and 7 had evidence of local or
distant disease progression by imaging or intraoperative
findings after neoadjuvant chemotherapy. Four additional
patients were excluded because they had received neoadju-
vant therapy with single-agent dasatinib on a clinical trial
(n ¼ 2), had known distant disease at diagnosis (n ¼ 1),
or had received neoadjuvant chemotherapy at Duke but
had undergone surgery elsewhere (n ¼ 1). This left 28 pa-
tients with confirmed persistent N2 nodal positivity after
neoadjuvant chemotherapy without evidence of disease
progression. The median follow-up was 22 months for all
patients and 92 months for the survivors.1176 The Journal of Thoracic and Cardiovascular SurInitial staging consisted of PET/CT (n¼ 18, 64%) or CT
(n ¼ 10, 36%). The median forced expiratory volume in 1
second and carbon monoxide diffusing capacity was 83%
(range, 42%–113%) and 75% (range, 46%–108%), re-
spectively. All patients initiated neoadjuvant chemotherapy
for stage IIIA (N2) NSCLC. Mediastinal lymph nodes were
pathologically confirmed in 23 (82%) and presumed posi-
tive by imaging studies in 5 patients (18%). The patient
and treatment characteristics can be found in Table 1. In
general, this cohort of patients had fairly small primary tu-
mors with a median size of 3 cm. Similarly, the N2 disease
burden was minimal, with a median size of the largest N2
node of 1.5 cm (range,<1–3) and a median number of
radiographically involved N2 nodal stations of 1 (range,
0–3). Of the patients undergoing initial mediastinscopy,
the median number of pathologically involved N2 nodal
stations was 1 (range, 1–2).
A variety of chemotherapy regimens was used, primarily
carboplatin combined with vinorelbine or paclitaxelgery c November 2011
FIGURE 1. Outline of patients and treatment administered after neoadju-
vant chemotherapy.
FIGURE 2. Kaplan-Meier curve demonstrating overall survival (OS),
disease-free survival, and local control for entire cohort of patients with
persistent N2 disease after neoadjuvant chemotherapy.
FIGURE 3. Kaplan-Meier curve demonstrating overall survival (OS) for
patients with persistent N2 disease undergoing resection versus nonopera-
tive treatment.
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S(Table 1). The median number of cycles was 2 (range, 2–4).
After completing neoadjuvant chemotherapy, imaging was
repeated in all patients (CT in 86% and PET/CT in 14%).
A response to chemotherapy was noted in 23 (82%), and
stable disease was noted in 5 (18%), with no patients
achieving a complete response by imaging.
Figure 1 details the subsequent treatment for all 28 pa-
tients and provides pathologic data regarding the frozen
section results of initial intraoperative N2 sampling,
whether all previously documented pathologically involved
N2 lymph node stations were sampled, and whether a R0 re-
section was performed. In brief, resection was performed in
22 of 28 patients and consisted of lobectomy in 14, pneumo-
nectomy in 2, and wedge/segmentectomy in 6. An R0 resec-
tion was achieved in 21 of 22 patients, with 1 patient
receiving R1 resection because of a positive surgical margin
after chest wall resection. The median number of patholog-
ically positive mediastinal lymph node stations after resec-
tion was 1. No postoperative deaths occurred. Of the 22
patients undergoing lung resection, 13 (59%) received post-
operative RT and 7 (32%) received additional chemother-
apy postoperatively. One patient was lost to follow-up,
and it was unknown whether they had received any adjuvant
therapy.
The remaining 6 patients did not undergo resection. The
stated reason for all patients was persistent N2 disease de-
tected during mediastinoscopy or video-assisted thoracic
surgery exploration. Of these, 4 patients received radiother-
apy (dose range, 60–70 Gy) to definitive doses, 3 of whom
received additional concurrent chemotherapy. Two patients
were referred for definitive radiotherapy at outside institu-
tions but the receipt of such could not be documented.
The median survival for all patients was 22 months. The
overall and disease-free survival rate at 1, 3, and 5 years was
75%, 37%, and 37% and 50%, 23%, and 19%, respec-
tively (Figure 2). The local disease control rate at 1, 3,
and 5 years was 73%, 53%, and 53%, respectively.
The overall survival rate at 5 years was similar between
patients undergoing resection (34%) and those receiving
definitive radiotherapy with or without chemotherapy
(40%; P ¼ .73), as demonstrated in Figure 3. At 5 years,
the overall survival rate (52% vs 30%, P ¼ .23), disease-The Journal of Thoracic and Carfree survival rate (28% vs 10%, P ¼ .1), and local control
rate (76% vs 51%, P¼ .40) were not significantly different
statistically between those patients with negative frozen
section mediastinal lymph node sampling and those patients
with positive frozen section mediastinal lymph node sam-
pling, although the numbers in each group were small.diovascular Surgery c Volume 142, Number 5 1177




The optimal approach for resectable N2 NSCLC remains
controversial. Neoadjuvant chemotherapy has been shown
to improve survival relative to surgery alone in some,4,16,17
but not all,3,18 randomized trials. Several prospective studies
have shown that a mediastinal pathologic complete response
is associated with improved outcomes after surgery
compared with patients with residual N2 disease.2,10-12 In
fact, most studies have shown that long-term survival is less
than 10% to 15% when patients remain N2 positive after
neoadjuvant chemotherapy, prompting some to question the
role of surgery in this group of patients.2,11,12 However,
appropriate adjuvant therapies, including radiotherapy and
additional chemotherapy, might be associated with better
outcomes in these patients.
Although neoadjuvant chemoradiotherapy is also widely
used for patients with N2 disease, this report focuses on
patients treated with preoperative chemotherapy, because
this is the preferred approach at our institution owing to
the fewer postoperative complications19 and the ability to
proceed with an uninterrupted course of radiotherapy if
resection is not ultimately performed.
In the present study, patients with disease progression
during neoadjuvant chemotherapy were excluded from the
analysis. This was a relatively small number of patients
(n ¼ 7), and most studies have shown that disease progres-
sion during chemotherapy is relatively uncommon.6,16,17
Most patients in our study with persistent N2 disease
after neoadjuvant chemotherapy proceeded to surgical re-
section (79%). Many received postoperative radiotherapy
and/or additional chemotherapy. Those patients who did
not undergo resection generally received definitive radio-
therapy (60 Gy), many with concurrent chemotherapy.
With this approach, the actuarial overall survival rate at
5 years was 37%, demonstrating that in appropriately
selected patients, persistent disease after neoadjuvant che-
motherapy does not necessarily carry a grim prognosis
and perhaps aggressive local therapy is warranted.
These somewhat unexpected high survival rates could be
due to several reasons. First, although the number of
patients was small, those patients with progression during
chemotherapy were excluded. Second, the burden of N2
disease in our series was small, with a median number of in-
volved N2 lymph nodes of 1 and a median size of 1.5 cm.
However, patients with bulky or multistation N2 disease
are generally not considered optimal candidates for surgery
at our institution, and most would not have received neoad-
juvant chemotherapy. Third, the patients considered for sur-
gery are generally younger, with a better performance
status, than many patients with stage IIIA disease treated
with a nonsurgical approach. Finally, patients received an
aggressive, often trimodality approach, which might have
decreased the risk of disease recurrence.1178 The Journal of Thoracic and Cardiovascular SurOur group has previously published a comparison of pa-
tients receiving neoadjuvant chemotherapy versus chemo-
radiotherapy for IIIA (N2) NSCLC.20 For the subgroup of
patients (n ¼ 10) who achieved a mediastinal pathologic
complete response to neoadjuvant chemotherapy, the
3-year overall survival rate was 40%. This compares with
37% for patients with persistent N2 disease in our analysis.
Other published data of contemporary phase II and III stud-
ies have demonstrated a 3-year overall survival rate of
61%2 and a 5-year overall survival rate ranging from
29% to 44%11,21 after preoperative chemotherapy for
patients achieving nodal downstaging to N0 or N1.
Although overall survival rates of this magnitude were not
reached in the present study, the outcomes were much
better than expected for a subgroup of patients who did
not respond favorably to chemotherapy.
Our study was limited by the small numbers and could
not address an important question regarding the optimal
local treatment modality for patients with persistent N2
disease. It appears that both surgery and definitive radio-
therapy can provide reasonable local control and survival.
However, only a few patients in our series received defini-
tive radiotherapy. Our experience suggests that local ther-
apy (surgery and/or radiotherapy) provides some benefit
and should be considered in this population of patients. A
definitive course of radiotherapy is generally recommended
if resection is not performed (60 Gy), ideally with concur-
rent chemotherapy.
We acknowledge other weaknesses and potential biases
inherent in this retrospective study. Not all patients under-
went PET imaging at the initial diagnosis. However, the out-
comes were expected to be better owing to stage migration
when more sensitive imaging modalities are used in the
staging workup. Furthermore, not all patients had upfront
pathologic staging of the mediastinum. That said, all pa-
tients had pathologic confirmation of persistent N2 disease
after completing neoadjuvant chemotherapy. Finally, it is
acknowledged that this represents a select group of patients
still thought to be appropriate surgical candidates despite
harboring residual mediastinal disease. Whether similar re-
sults would be achieved with a broader N2 population is not
known.
It should be noted that our general approach after neoad-
juvant chemotherapy is to reserve resection for patients with
no evidence of residual mediastinal disease or at most
single-station, microscopic persistent N2 disease that would
not necessitate pneumonectomy. We generally use neoadju-
vant chemotherapy alone, instead of chemoradiotherapy,
thus allowing an uninterrupted course of definitive radio-
therapy if resection is not performed.
Our study was limited by the small numbers; thus, addi-
tional hypothesis-generating subgroup analyses were not
possible. As mentioned, no differences in outcomes weregery c November 2011
Higgins et al General Thoracic Surgeryseen in the patients receiving surgery versus definitive
radiotherapy. It was not possible to assess other important
issues, such as the type of surgery, role of postoperative
radiotherapy, optimal dose of radiotherapy, importance of
additional chemotherapy, and so forth. However, it should
be noted that most patients were treated with a comprehen-
sive approach aimed to control both local and distant dis-
ease. A comparison of the clinical outcomes between
patients with negative versus positive mediastinal sampling
before lung resection demonstrated no statistically signifi-
cant differences in the clinical outcomes, although clear
trends were seen in favor of those with negative findings
on frozen section analysis, suggesting that the overall N2
disease burden is likely prognostic.G
T
SCONCLUSIONS
With appropriate adjuvant therapy, local modalities
should be considered in patients with persistent N2 disease
after neoadjuvant chemotherapy.References
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